Download PDF
Semin Reprod Med 2014; 32(03): 222-229
DOI: 10.1055/s-0034-1371094
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Menopausal Implications of Polycystic Ovarian Syndrome

Rashmi Kudesia
1   Division of Reproductive Endocrinology and Infertility, Department of Obstetrics & Gynecology and Women's Health, Albert Einstein College of Medicine
,
Genevieve S. Neal-Perry
1   Division of Reproductive Endocrinology and Infertility, Department of Obstetrics & Gynecology and Women's Health, Albert Einstein College of Medicine
2   Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
08 April 2014 (online)

    Permissions and Reprints

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrinopathy affecting up to 8 to 10% of reproductive-aged women. Although the medical and metabolic consequences of PCOS are well-described in young reproductive-aged women, its impact on female reproductive senescence and the menopausal transition is poorly understood. This review summarizes current knowledge regarding the effect of PCOS is menopausal and perimenopausal women. We also highlight areas that are ripe for clinical research.

Keywords

menopause - PCOS - hormone therapy
 

  • References

  • 1 Carmina E. Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines. Minerva Ginecol 2004; 56 (1) 1-6
    PubMedGoogle Scholar
  • 2 Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab 2006; 91 (3) 786-789
    CrossrefPubMedGoogle Scholar
  • 3 Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome; towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, , eds. Polycystic Ovary Syndrome. Boston: Blackwell Scientific; 1992: 377-384
    Google Scholar
  • 4 Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 2006; 91 (3) 781-785
    CrossrefPubMedGoogle Scholar
  • 5 Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 2012; 33 (6) 981-1030
    CrossrefPubMedGoogle Scholar
  • 6 Taffe JR, Dennerstein L. Menstrual patterns leading to the final menstrual period. Menopause 2002; 9 (1) 32-40
    CrossrefPubMedGoogle Scholar
  • 7 Van Voorhis BJ, Santoro N, Harlow S, Crawford SL, Randolph J. The relationship of bleeding patterns to daily reproductive hormones in women approaching menopause. Obstet Gynecol 2008; 112 (1) 101-108
    CrossrefPubMedGoogle Scholar
  • 8 Vollman RF. The menstrual cycle. Major Probl Obstet Gynecol 1977; 7: 1-193
    PubMedGoogle Scholar
  • 9 Dahlgren E, Johansson S, Lindstedt G , et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992; 57 (3) 505-513
    PubMedGoogle Scholar
  • 10 Elting MW, Kwee J, Korsen TJ, Rekers-Mombarg LT, Schoemaker J. Aging women with polycystic ovary syndrome who achieve regular menstrual cycles have a smaller follicle cohort than those who continue to have irregular cycles. Fertil Steril 2003; 79 (5) 1154-1160
    CrossrefPubMedGoogle Scholar
  • 11 Harlow SD, Gass M, Hall JE , et al; STRAW + 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012; 97 (4) 1159-1168
    CrossrefPubMedGoogle Scholar
  • 12 Shah D, Bansal S. Polycystic ovaries - beyond menopause. Climacteric . Epub, October 28, 2013
    PubMedGoogle Scholar
  • 13 Schmidt J, Brännström M, Landin-Wilhelmsen K, Dahlgren E. Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls. J Clin Endocrinol Metab 2011; 96 (7) 2178-2185
    CrossrefPubMedGoogle Scholar
  • 14 Hudecova M, Holte J, Moby L , et al. Androgen levels, insulin sensitivity, and early insulin response in women with polycystic ovary syndrome: a long-term follow-up study. Fertil Steril 2011; 95 (3) 1146-1148
    CrossrefPubMedGoogle Scholar
  • 15 Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005; 90 (7) 3847-3853
    CrossrefPubMedGoogle Scholar
  • 16 McConnell DS, Stanczyk FZ, Sowers MR, Randolph Jr JF, Lasley BL. Menopausal transition stage-specific changes in circulating adrenal androgens. Menopause 2012; 19 (6) 658-663
    CrossrefPubMedGoogle Scholar
  • 17 Stanczyk FZ, Lee JS, Santen RJ. Standardization of steroid hormone assays: why, how, and when?. Cancer Epidemiol Biomarkers Prev 2007; 16 (9) 1713-1719
    CrossrefPubMedGoogle Scholar
  • 18 Alsamarai S, Adams JM, Murphy MK , et al. Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. J Clin Endocrinol Metab 2009; 94 (12) 4961-4970
    CrossrefPubMedGoogle Scholar
  • 19 Hudecova M, Holte J, Olovsson M, Sundström Poromaa I. Long-term follow-up of patients with polycystic ovary syndrome: reproductive outcome and ovarian reserve. Hum Reprod 2009; 24 (5) 1176-1183
    CrossrefPubMedGoogle Scholar
  • 20 Webber LJ, Stubbs S, Stark J , et al. Formation and early development of follicles in the polycystic ovary. Lancet 2003; 362 (9389) 1017-1021
    CrossrefPubMedGoogle Scholar
  • 21 van Disseldorp J, Faddy MJ, Themmen AP , et al. Relationship of serum antimüllerian hormone concentration to age at menopause. J Clin Endocrinol Metab 2008; 93 (6) 2129-2134
    CrossrefPubMedGoogle Scholar
  • 22 Dólleman M, Faddy MJ, van Disseldorp J , et al. The relationship between anti-Müllerian hormone in women receiving fertility assessments and age at menopause in subfertile women: evidence from large population studies. J Clin Endocrinol Metab 2013; 98 (5) 1946-1953
    CrossrefPubMedGoogle Scholar
  • 23 Mulders AG, Laven JS, Eijkemans MJ, de Jong FH, Themmen AP, Fauser BC. Changes in anti-Müllerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility. Hum Reprod 2004; 19 (9) 2036-2042
    CrossrefPubMedGoogle Scholar
  • 24 Tehrani FR, Solaymani-Dodaran M, Hedayati M, Azizi F. Is polycystic ovary syndrome an exception for reproductive aging?. Hum Reprod 2010; 25 (7) 1775-1781
    CrossrefPubMedGoogle Scholar
  • 25 Holte J, Bergh T, Gennarelli G, Wide L. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women. Clin Endocrinol (Oxf) 1994; 41 (4) 473-481
    CrossrefPubMedGoogle Scholar
  • 26 Schmidt J, Landin-Wilhelmsen K, Brännström M, Dahlgren E. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study. J Clin Endocrinol Metab 2011; 96 (12) 3794-3803
    CrossrefPubMedGoogle Scholar
  • 27 Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18 (6) 774-800
    CrossrefPubMedGoogle Scholar
  • 28 Solomon CG, Hu FB, Dunaif A , et al. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA 2001; 286 (19) 2421-2426
    CrossrefPubMedGoogle Scholar
  • 29 Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010; 16 (4) 347-363
    CrossrefPubMedGoogle Scholar
  • 30 Hudecova M, Holte J, Olovsson M, Larsson A, Berne C, Poromaa IS. Diabetes and impaired glucose tolerance in patients with polycystic ovary syndrome—a long term follow-up. Hum Reprod 2011; 26 (6) 1462-1468
    CrossrefPubMedGoogle Scholar
  • 31 Fauser BC, Tarlatzis BC, Rebar RW , et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012; 97 (1) 28-38.e25
    CrossrefPubMedGoogle Scholar
  • 32 Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003; 163 (4) 427-436
    CrossrefPubMedGoogle Scholar
  • 33 Glueck CJ, Dharashivkar S, Wang P , et al. Obesity and extreme obesity, manifest by ages 20-24 years, continuing through 32-41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy. Eur J Obstet Gynecol Reprod Biol 2005; 122 (2) 206-212
    CrossrefPubMedGoogle Scholar
  • 34 Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987; 65 (3) 499-507
    CrossrefPubMedGoogle Scholar
  • 35 Panidis D, Tziomalos K, Chatzis P , et al. Association between menstrual cycle irregularities and endocrine and metabolic characteristics of the polycystic ovary syndrome. Eur J Endocrinol 2013; 168 (2) 145-152
    CrossrefPubMedGoogle Scholar
  • 36 Panidis D, Tziomalos K, Macut D , et al. Age- and body mass index-related differences in the prevalence of metabolic syndrome in women with polycystic ovary syndrome. Gynecol Endocrinol 2013; 29 (10) 926-930
    CrossrefPubMedGoogle Scholar
  • 37 ESHRE Capri Workshop Group. Hormones and cardiovascular health in women. Hum Reprod Update 2006; 12 (5) 483-497
    CrossrefPubMedGoogle Scholar
  • 38 Grundy SM, Cleeman JI, Daniels SR , et al; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112 (17) 2735-2752
    CrossrefPubMedGoogle Scholar
  • 39 Bajuk Studen K, Jensterle Sever M, Pfeifer M. Cardiovascular risk and subclinical cardiovascular disease in polycystic ovary syndrome. Front Horm Res 2013; 40: 64-82
    PubMedGoogle Scholar
  • 40 Spanos N, Tziomalos K, Macut D , et al. Adipokines, insulin resistance and hyperandrogenemia in obese patients with polycystic ovary syndrome: cross-sectional correlations and the effects of weight loss. Obes Facts 2012; 5 (4) 495-504
    CrossrefPubMedGoogle Scholar
  • 41 Murri M, Luque-Ramírez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update 2013; 19 (3) 268-288
    CrossrefPubMedGoogle Scholar
  • 42 Toulis KA, Goulis DG, Mintziori G , et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update 2011; 17 (6) 741-760
    CrossrefPubMedGoogle Scholar
  • 43 Beydoun HA, Beydoun MA, Wiggins N, Stadtmauer L. Relationship of obesity-related disturbances with LH/FSH ratio among post-menopausal women in the United States. Maturitas 2012; 71 (1) 55-61
    Google Scholar
  • 44 Hudecova M, Holte J, Olovsson M, Larsson A, Berne C, Sundstrom-Poromaa I. Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: long-term follow-up. Fertil Steril 2011; 96 (5) 1271-1274
    CrossrefPubMedGoogle Scholar
  • 45 Elting MW, Korsen TJ, Schoemaker J. Obesity, rather than menstrual cycle pattern or follicle cohort size, determines hyperinsulinaemia, dyslipidaemia and hypertension in ageing women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2001; 55 (6) 767-776
    CrossrefPubMedGoogle Scholar
  • 46 Carmina E. PCOS: metabolic impact and long-term management. Minerva Ginecol 2012; 64 (6) 501-505
    PubMedGoogle Scholar
  • 47 Carmina E. Obesity, adipokines and metabolic syndrome in polycystic ovary syndrome. Front Horm Res 2013; 40: 40-50
    PubMedGoogle Scholar
  • 48 Welt CK, Carmina E. Lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause. J Clin Endocrinol Metab 2013; 98 (12) 4629-4638
    CrossrefPubMedGoogle Scholar
  • 49 Shaw LJ, Bairey Merz CN, Azziz R , et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health—National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93 (4) 1276-1284
    CrossrefPubMedGoogle Scholar
  • 50 Krentz AJ, von Mühlen D, Barrett-Connor E. Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease. Menopause 2007; 14 (2) 284-292
    CrossrefPubMedGoogle Scholar
  • 51 Cibula D, Cífková R, Fanta M, Poledne R, Zivny J, Skibová J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000; 15 (4) 785-789
    CrossrefPubMedGoogle Scholar
  • 52 Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998; 51 (7) 581-586
    CrossrefPubMedGoogle Scholar
  • 53 Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb) 2000; 3 (2) 101-105
    CrossrefPubMedGoogle Scholar
  • 54 ESHRE Capri Workshop Group. Health and fertility in World Health Organization group 2 anovulatory women. Hum Reprod Update 2012; 18 (5) 586-599
    CrossrefPubMedGoogle Scholar
  • 55 Hosseinpanah F, Barzin M, Tehrani FR, Azizi F. The lack of association between polycystic ovary syndrome and metabolic syndrome: Iranian PCOS prevalence study. Clin Endocrinol (Oxf) 2011; 75 (5) 692-697
    CrossrefPubMedGoogle Scholar
  • 56 Da Fonseca AM, Bagnoli VR, Souza MA , et al. Impact of age and body mass on the intensity of menopausal symptoms in 5968 Brazilian women. Gynecol Endocrinol 2013; 29 (2) 116-118
    CrossrefPubMedGoogle Scholar
  • 57 Gambacciani M, Ciaponi M, Cappagli B , et al. Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women. J Clin Endocrinol Metab 1997; 82 (2) 414-417
    CrossrefPubMedGoogle Scholar
  • 58 Espeland MA, Stefanick ML, Kritz-Silverstein D , et al; Postmenopausal Estrogen-Progestin Interventions Study Investigators. Effect of postmenopausal hormone therapy on body weight and waist and hip girths. J Clin Endocrinol Metab 1997; 82 (5) 1549-1556
    CrossrefPubMedGoogle Scholar
  • 59 Rachoń D, Teede H. Ovarian function and obesity—interrelationship, impact on women's reproductive lifespan and treatment options. Mol Cell Endocrinol 2010; 316 (2) 172-179
    CrossrefPubMedGoogle Scholar
  • 60 Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online 2009; 19 (3) 398-405
    CrossrefPubMedGoogle Scholar
  • 61 Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod 2012; 27 (5) 1327-1331
    CrossrefPubMedGoogle Scholar
  • 62 Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A, Hughes C. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 1996; 88 (4 Pt 1) 554-559
    CrossrefPubMedGoogle Scholar
  • 63 Dumesic DA, Lobo RA. Cancer risk and PCOS. Steroids 2013; 78 (8) 782-785
    CrossrefPubMedGoogle Scholar
  • 64 Talamini R, Franceschi S, Favero A, Negri E, Parazzini F, La Vecchia C. Selected medical conditions and risk of breast cancer. Br J Cancer 1997; 75 (11) 1699-1703
    CrossrefPubMedGoogle Scholar
  • 65 Baron JA, Weiderpass E, Newcomb PA , et al. Metabolic disorders and breast cancer risk (United States). Cancer Causes Control 2001; 12 (10) 875-880
    CrossrefPubMedGoogle Scholar
  • 66 Gammon MD, Thompson WD. Polycystic ovaries and the risk of breast cancer. Am J Epidemiol 1991; 134 (8) 818-824
    PubMedGoogle Scholar
  • 67 Atiomo WU, El-Mahdi E, Hardiman P. Familial associations in women with polycystic ovary syndrome. Fertil Steril 2003; 80 (1) 143-145
    PubMedGoogle Scholar
  • 68 Adami S, Zamberlan N, Castello R, Tosi F, Gatti D, Moghetti P. Effect of hyperandrogenism and menstrual cycle abnormalities on bone mass and bone turnover in young women. Clin Endocrinol (Oxf) 1998; 48 (2) 169-173
    CrossrefPubMedGoogle Scholar
  • 69 Carmina E, Guastella E, Longo RA, Rini GB, Lobo RA. Correlates of increased lean muscle mass in women with polycystic ovary syndrome. Eur J Endocrinol 2009; 161 (4) 583-589
    CrossrefPubMedGoogle Scholar
  • 70 Good C, Tulchinsky M, Mauger D, Demers LM, Legro RS. Bone mineral density and body composition in lean women with polycystic ovary syndrome. Fertil Steril 1999; 72 (1) 21-25
    CrossrefPubMedGoogle Scholar
  • 71 Kassanos D, Trakakis E, Baltas CS , et al. Augmentation of cortical bone mineral density in women with polycystic ovary syndrome: a peripheral quantitative computed tomography (pQCT) study. Hum Reprod 2010; 25 (8) 2107-2114
    CrossrefPubMedGoogle Scholar
  • 72 To WW, Wong MW. A comparison of bone mineral density in normal weight and obese adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2012; 25 (4) 248-253
    CrossrefPubMedGoogle Scholar
  • 73 Schmidt J, Dahlgren E, Brännström M, Landin-Wilhelmsen K. Body composition, bone mineral density and fractures in late postmenopausal women with polycystic ovary syndrome - a long-term follow-up study. Clin Endocrinol (Oxf) 2012; 77 (2) 207-214
    CrossrefPubMedGoogle Scholar
  • 74 de Sousa G, Schlüter B, Buschatz D , et al. A comparison of polysomnographic variables between obese adolescents with polycystic ovarian syndrome and healthy, normal-weight and obese adolescents. Sleep Breath 2010; 14 (1) 33-38
    CrossrefPubMedGoogle Scholar
  • 75 Gopal M, Duntley S, Uhles M, Attarian H. The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovarian syndrome. Sleep Med 2002; 3 (5) 401-404
    CrossrefPubMedGoogle Scholar
  • 76 Nandalike K, Strauss T, Agarwal C , et al. Screening for sleep-disordered breathing and excessive daytime sleepiness in adolescent girls with polycystic ovarian syndrome. J Pediatr 2011; 159 (4) 591-596
    CrossrefPubMedGoogle Scholar
  • 77 Shreeve N, Cagampang F, Sadek K , et al. Poor sleep in PCOS; is melatonin the culprit?. Hum Reprod 2013; 28 (5) 1348-1353
    CrossrefPubMedGoogle Scholar
  • 78 Vgontzas AN, Legro RS, Bixler EO, Grayev A, Kales A, Chrousos GP. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 2001; 86 (2) 517-520
    CrossrefPubMedGoogle Scholar
  • 79 Guidozzi F. Sleep and sleep disorders in menopausal women. Climacteric 2013; 16 (2) 214-219
    CrossrefPubMedGoogle Scholar
  • 80 Veltman-Verhulst SM, Boivin J, Eijkemans MJ, Fauser BJ. Emotional distress is a common risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of 28 studies. Hum Reprod Update 2012; 18 (6) 638-651
    CrossrefPubMedGoogle Scholar
  • 81 Ching HL, Burke V, Stuckey BG. Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers. Clin Endocrinol (Oxf) 2007; 66 (3) 373-379
    CrossrefPubMedGoogle Scholar
  • 82 Jedel E, Waern M, Gustafson D , et al. Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Hum Reprod 2010; 25 (2) 450-456
    CrossrefPubMedGoogle Scholar
  • 83 Cronin L, Guyatt G, Griffith L , et al. Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 1998; 83 (6) 1976-1987
    CrossrefPubMedGoogle Scholar
  • 84 Ewens KG, Jones MR, Ankener W , et al. Type 2 diabetes susceptibility single-nucleotide polymorphisms are not associated with polycystic ovary syndrome. Fertil Steril 2011; 95 (8) 2538-2541 , e1–e6
    CrossrefPubMedGoogle Scholar
  • 85 Ewens KG, Jones MR, Ankener W , et al. FTO and MC4R gene variants are associated with obesity in polycystic ovary syndrome. PLoS ONE 2011; 6 (1) e16390
    CrossrefPubMedGoogle Scholar
  • 86 Goodarzi MO, Jones MR, Li X , et al. Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. J Med Genet 2012; 49 (2) 90-95
    CrossrefPubMedGoogle Scholar